Development and internal validation of a pretreatment magnetic resonance imaging-based radiomics prediction model for 1-year overall survival in treatment-naïve patients with hepatocellular carcinoma receiving transarterial chemoembolization combined with targeted therapy and immune checkpoint inhib
Background Reliable pretreatment tools to identify treatment-naïve patients with intermediate-to-advanced hepatocellular carcinoma (HCC) who may benefit from this combination are lacking. We developed and internally validated a clinical-radiomics model based on pretreatment T2-weighted fat-suppressed magnetic resonance...